Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02842021 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
A Phase 2 study, sponsored by Sol-Gel Technologies.
- Terminated
- Registry status
- Phase 2
- Development phase
- 283
- Enrollment target
NCT02842021 is a Phase 2 study that was terminated before completion, run by Sol-Gel Technologies. The registered enrollment target is 283 participants.
The verdict
NCT02842021, a Phase 2 study, was terminated before completion, sponsored by Sol-Gel Technologies.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 283 participants
- Enrollment target
Study Summary
To assess the efficacy and safety of a combination product S2G6T-1 compared to its monads and vehicle, applied twice daily for 7 days, in the treatment of symptomatic inflammatory interdigital tinea pedis in subjects 12 years of age and older. The results of this study will be utilized to perform power calculations for the Phase 3 pivotal trials.
Interventions
- DRUG S2G6T-1
- DRUG S2G6T-2
- DRUG S2G6T-3
- DRUG S2G6T-4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 283 participants |
| Start Date | 2016-09 |
| Est. Completion | 2017-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02842021
The ClinicalTrials.gov registry entry for NCT02842021 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 283 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sol-Gel Technologies, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which S2G6T-1 is the first listed.
NCT02842021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02842021 about?
NCT02842021 is a clinical study titled "Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis". To assess the efficacy and safety of a combination product S2G6T-1 compared to its monads and vehicle, applied twice daily for 7 days, in the treatment of symptomatic inflammatory interdigital tinea pedis in subjects 12 years of age and older. The results of this study will be utilized to perform po...
What is the current status of trial NCT02842021?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 283 participants. The study started on 2016-09. Estimated completion is 2017-10.
What interventions are being tested in trial NCT02842021?
The interventions under investigation include: S2G6T-1 (DRUG), S2G6T-2 (DRUG), S2G6T-3 (DRUG), S2G6T-4 (DRUG).
Who is sponsoring clinical trial NCT02842021?
This trial is sponsored by Sol-Gel Technologies, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.